These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19589292)

  • 21. [Biologics in the treatment of psoriasis].
    Dissemond J; Grabbe S
    MMW Fortschr Med; 2006 Sep; 148(38):42-4. PubMed ID: 17036963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.
    Katugampola RP; Lewis VJ; Finlay AY
    Br J Dermatol; 2007 May; 156(5):945-50. PubMed ID: 17388922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
    N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.
    Zachariae C; Mørk NJ; Reunala T; Lorentzen H; Falk E; Karvonen SL; Johannesson A; Claréus B; Skov L; Mørk G; Walker S; Qvitzau S
    Acta Derm Venereol; 2008; 88(5):495-501. PubMed ID: 18779890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis.
    Luger TA; Barker J; Lambert J; Yang S; Robertson D; Foehl J; Molta CT; Boggs R
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):896-904. PubMed ID: 19453794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
    Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome.
    Driessen RJ; Berends MA; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2008 May; 158(5):1098-106. PubMed ID: 18384440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
    Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
    Martyn-Simmons CL; Green L; Ash G; Groves RW; Smith CH; Barker JN
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1394-7. PubMed ID: 19573024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and economic impact of etanercept in real-life: a prospective, non-interventional study of etanercept in the treatment of patients with moderate to severe plaque psoriasis in private dermatologist settings (ESTHER).
    Larsen CG; Andersen PH; Lorentzen H; Zachariae C; Huldt-Nystrøm T; Dotterud LK; Lindkvist RM; Qvitzau S
    Eur J Dermatol; 2013; 23(6):774-81. PubMed ID: 24334009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial.
    Thaçi D; Galimberti R; Amaya-Guerra M; Rosenbach T; Robertson D; Pedersen R; Yang S; Kuligowski M; Boggs R
    J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):900-6. PubMed ID: 23848989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efalizumab therapy for psoriasis in patients with inadequate responses to etanercept.
    Kramer JM; Turner JE
    Am J Clin Dermatol; 2009; 10(2):134-40. PubMed ID: 19222255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytomegalovirus complicating biological immunosuppressive therapy in two patients with psoriasis receiving treatment with etanercept or efalizumab.
    Petersen B; Lorentzen H
    Acta Derm Venereol; 2008; 88(5):523-4. PubMed ID: 18779901
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies.
    Prignano F; Ricceri F; Pescitelli L; Buggiani G; Troiano M; Zanieri F; Rossari S; Lotti T
    Curr Med Res Opin; 2009 Sep; 25(9):2311-6. PubMed ID: 19635043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH
    J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.
    Tyring S; Gottlieb A; Papp K; Gordon K; Leonardi C; Wang A; Lalla D; Woolley M; Jahreis A; Zitnik R; Cella D; Krishnan R
    Lancet; 2006 Jan; 367(9504):29-35. PubMed ID: 16399150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological treatments for moderate-to-severe psoriasis: indirect comparison.
    Galván-Banqueri M; Marín Gil R; Santos Ramos B; Bautista Paloma FJ
    J Clin Pharm Ther; 2013 Apr; 38(2):121-30. PubMed ID: 23442134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
    Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
    Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy.
    Hamilton TK
    J Drugs Dermatol; 2008 Nov; 7(11):1089-93. PubMed ID: 19110745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.